Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05717712 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 28, 2024 (before its estimated January 4, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
Capital Medical University
105 trials monitored
See 5 trials at risk
Glioma
1,251 trials monitored
See 88 trials at risk
This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).
Trial Details
NCT Number NCT05717712
Lead Sponsor Capital Medical University
Conditions
(from sponsor)		 Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
Related terms Diffuse Intrinsic Pontine Glioma, Drug-Related Side Effects and Adverse Reactions
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov